Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity

Anindita Bhoumik, Nic Jones, Ze'Ev Ronai

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

The notorious resistance of melanoma cells to drug treatment can be overcome by expression of a 50-aa peptide derived from activating transcription factor 2 (ATF250-100). Here we demonstrate that ATF2 50-100 induced apoptosis by sequestering ATF2 to the cytoplasm, thereby inhibiting its transcriptional activities. Furthermore, ATF2 50-100 binds to c-Jun N-terminal kinase (JNK) and increases its activity. Mutation within ATF250-100 that impairs association with JNK and the inhibition of JNK or c-Jun expression by RNA interference (RNAi) reduces the degree of ATF250-100-induced apoptosis. In contrast, TAM67, a dominant negative of the Jun family of transcription factors, or JunD RNAi attenuates sensitization of melanoma cells expressing ATF2 50-100 to apoptosis after treatment with anisomycin, which is used as a model drug. Mutations within the JNK binding region of ATF2 50-100 or expression of TAM67 or JunD RNAi attenuates inhibition of melanoma's tumorigenicity by ATF250-100. We conclude that inhibition of ATF2 in concert with increased JNK/Jun and JunD activities is central for the sensitization of melanoma cells to apoptosis and inhibition of their tumorigenicity.

Original languageEnglish
Pages (from-to)4222-4227
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue number12
DOIs
StatePublished - 23 Mar 2004

Fingerprint

Dive into the research topics of 'Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity'. Together they form a unique fingerprint.

Cite this